All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Phase IV B1931030 study: Inotuzumab ozogamicin dose optimization in adults with R/R B-ALL
Bookmark this article
|
The anti-CD22 ADC inotuzumab ozogamicin (InO) was approved by the FDA for the treatment of adult patients with R/R B-ALL in 2017 and for pediatric patients in 2024.1 The FDA subsequently issued a post-marketing requirement due to concerns that the proposed dose of 1.8 mg/m2/cycle may not provide optimal InO efficacy/safety balancing.11 The phase IV dose optimization study B1931030 (NCT03677596) therefore evaluated the risk-benefit profile of 1.2 mg/m2/cycle (run-in + randomized, n = 64) vs 1.8 mg/m2/cycle (n = 38) doses of InO in adults with R/R B-ALL who were eligible for HSCT.1 The primary objectives were to evaluate the CR/CRi, MRD-negativity, and VOD rates for the two InO dose levels.1 Results from this trial were presented at the 66th ASH Annual Meeting and Exposition by DeAngelo.1 |
| Key learnings |
|
Efficacy was comparable at 1.2 mg/m2/cycle and 1.8 mg/m2/cycle doses; CR/CRi rates were 71.9% vs 68.4%, MRD-negativity was 71.7% vs 69.2%, DoR was 5.5 months vs 6.8 months, PFS rates were 5.3 months vs 6.3 months, and OS durations were 7.6 months vs 8.1 months. |
| VOD rates were higher at 1.2 mg/m2 vs 1.8 mg/m2 (12.5% vs 5.3%). The 1.8 mg/m2 dose had a higher CUI vs the 1.2 mg/m2 dose. |
| Safety was comparable between 1.2 mg/m2 and 1.8 mg/m2 doses, with Grade 3–4 AEs reported in 46.9% vs 47.4% and SAEs in 67.2% and 55.3% of patients, respectively. |
| The favorable efficacy and safety results support the use of the FDA-approved dose of 1.8 mg/m2/cycle of InO compared to a lower dose of 1.2 mg/m2/cycle in adult patients with R/R B-ALL. |
Abbreviations: ADC, antibody–drug conjugate; AE, adverse event; B-ALL, B-cell acute lymphoblastic leukemia; CR/CRi, complete remission with incomplete hematologic recovery; CUI, clinical utility index; DoR, duration of response; FDA, U.S. Food and Drug Administration; HSCT, hematopoietic stem cell transplant; InO, inotuzumab ozogamicin; MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory; SAE, serious AE; VOD, veno-occlusive disease.
- DeAngelo DJ. Dose optimization of inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Oral abstract #732. 66th American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 7-10, 2024; San Diego, US.
Your opinion matters
22 votes - 85 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox